» Articles » PMID: 28604806

Prostaglandin E2 Inhibits Tr1 Cell Differentiation Through Suppression of C-Maf

Overview
Journal PLoS One
Date 2017 Jun 13
PMID 28604806
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Prostaglandin E2 (PGE2), a major lipid mediator abundant at inflammatory sites, acts as a proinflammatory agent in models of inflammatory/autoimmune diseases by promoting CD4 Th1/Th17 differentiation. Regulatory T cells, including the IL-10 producing Tr1 cells counterbalance the proinflammatory activity of effector Th1/Th17 cells. Tr1 cell differentiation and function are induced by IL-27, and depend primarily on sustained expression of c-Maf in addition to AhR and Blimp-1. In agreement with the in vivo proinflammatory role of PGE2, here we report for the first time that PGE2 inhibits IL-27-induced differentiation and IL-10 production of murine CD4+CD49b+LAG-3+Foxp3- Tr1 cells. The inhibitory effect of PGE2 was mediated through EP4 receptors and induction of cAMP, leading to a significant reduction in c-Maf expression. Although PGE2 reduced IL-21 production in differentiating Tr1 cells, its inhibitory effect on Tr1 differentiation and c-Maf expression also occurred independent of IL-21 signaling. PGE2 did not affect STAT1/3 activation, AhR expression and only marginally reduced Egr-2/Blimp-1 expression. The effect of PGE2 on CD4+CD49b+LAG-3+ Tr1 differentiation was not associated with either induction of Foxp3 or IL-17 production, suggesting a lack of transdifferentiation into Foxp3+ Treg or effector Th17 cells. We recently reported that PGE2 inhibits the expression and production of IL-27 from activated conventional dendritic cells (cDC) in vivo and in vitro. The present study indicates that PGE2 also reduces murine Tr1 differentiation and function directly by acting on IL-27-differentiating Tr1 cells. Together, the ability of PGE2 to inhibit IL-27 production by cDC, and the direct inhibitory effect on Tr1 differentiation mediated through reduction in c-Maf expression, represent a new mechanistic perspective for the proinflammatory activity of PGE2.

Citing Articles

Crisdesalazine alleviates inflammation in an experimental autoimmune encephalomyelitis multiple sclerosis mouse model by regulating the immune system.

Park S, Oh Y, Lim G, An J, Lee J, Gwag B BMC Neurosci. 2025; 26(1):1.

PMID: 39754048 PMC: 11699678. DOI: 10.1186/s12868-024-00920-w.


Differential lipid signaling from CD4 and CD8 T cells contributes to type 1 diabetes development.

White T, Almutairi A, Gai-Tusing Y, Stephenson D, Stephenson B, Chalfant C Front Immunol. 2024; 15():1444639.

PMID: 39359722 PMC: 11445035. DOI: 10.3389/fimmu.2024.1444639.


An association between elevated telomerase reverse transcriptase expression and the immune tolerance disruption of dendritic cells.

Xu X, Mo L, Liao Y, Zhang K, Zhang H, Liu L Cell Commun Signal. 2024; 22(1):284.

PMID: 38783329 PMC: 11112790. DOI: 10.1186/s12964-024-01650-6.


Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators.

Perez-Hernandez J, Chiurchiu V, Perruche S, You S Front Immunol. 2021; 12:768133.

PMID: 34868025 PMC: 8635229. DOI: 10.3389/fimmu.2021.768133.


The Signaling Pathway of PGE and Its Regulatory Role in T Cell Differentiation.

An Y, Yao J, Niu X Mediators Inflamm. 2021; 2021:9087816.

PMID: 34867083 PMC: 8641993. DOI: 10.1155/2021/9087816.


References
1.
Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y . The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev. 2013; 65(3):1010-52. DOI: 10.1124/pr.112.007195. View

2.
Boomer J, Green J . An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol. 2010; 2(8):a002436. PMC: 2908766. DOI: 10.1101/cshperspect.a002436. View

3.
Jeon S, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H . Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog. 2012; 8(5):e1002714. PMC: 3364948. DOI: 10.1371/journal.ppat.1002714. View

4.
Wu H, Quintana F, da Cunha A, Dake B, Koeglsperger T, Starossom S . In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS One. 2011; 6(8):e23618. PMC: 3160310. DOI: 10.1371/journal.pone.0023618. View

5.
Gregori S, Passerini L, Roncarolo M . Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy. Front Immunol. 2015; 6:593. PMC: 4658444. DOI: 10.3389/fimmu.2015.00593. View